Pregnancy, childbirth and the postpartum period: opportunities to improve lifetime outcomes for women with non-communicable diseases

Abstract

Non-communicable diseases (NCDs), such as cardiovascular disease, malignant neoplasms, chronic respiratory diseases and diabetes, are the primary cause of death and disability among women,^{1, 2} with women remaining susceptible throughout their life spans.³ Estimates indicate that women in most countries (88%) have a higher probability of dying before the age of 70 from an NCD than from communicable, perinatal and nutritional conditions combined.⁴ Most premature deaths due to NCDs (86%) occur in low and middle-income countries (LMICs),⁵ but health inequalities persist in high income countries (HICs) and NCDs affect some population groups more than others.⁴ In addition, the effects of the pandemic of NCDs on global health are intertwined with effects of climate change.⁶

Globally, the proportion of deaths due to NCDs in women of reproductive age increased from 44% in 2010 to 52% in 2019.⁷ Although this trend has declined since the start of the coronavirus disease 2019 (COVID-19) pandemic, the absolute number of NCD deaths has continued to increase.⁷ In 2021, the most common NCD causes of death among women globally were cardiovascular disease (30% of total deaths in women); malignant neoplasms (14%); respiratory diseases (6%); neurological conditions (5%); and diabetes, digestive diseases and genitourinary diseases (3%).²

The United Nations 2030 Agenda for Sustainable Development recognises both NCDs and maternal mortality rates as major challenges^{8, 9} (Box 1). Globally, progress towards the United Nations goals is variable. Reduced mortality from NCDs in women by 2030 is attainable in only 35 mostly HICs (19%), and requires a slight acceleration in decline in 50 countries (27%); with these goals not likely to be achieved in 86 countries (46%).⁴ In 15 countries (8%), NCD-related mortality rates have stagnated or increased. Although the global maternal mortality rate decreased between 2000 and 2020, it significantly increased between 2016 and 2020 in Europe, North America, Latin America and the Caribbean, and between 2000 and 2020 in eight countries, including the United States.¹⁰ The leading direct cause of maternal mortality is haemorrhage (27.1% globally); however, a similar proportion (27.5%) results from indirect causes, most of which pre-date pregnancy (> 70%).¹¹ In Australia in 2018–2020, cardiovascular disease was one of the leading causes of maternal mortality¹² (Box 2).

National statistics can mask the greater burden of NCDs for women in some groups, which is often exacerbated by intersecting forms of disadvantage.¹³ Disparities in the impact of NCDs on subgroups of women in a HIC, such as Australia, provide an example of this where First Nations women are at higher risk of mortality from some NCDs^{14, 15} and rates of disability-adjusted life years (DALYs) vary with socio-economic status and remoteness (Box 3).¹⁶

Most LMICs suffer from a complex burden of disease comprising infections, undernutrition and maternal mortality; the emerging challenge of NCDs; and problems directly related to globalisation, such as pandemics and climate change.¹⁷ Recent evidence suggests that women in low- and middle-income countries are also more likely to experience “multimorbidity” (two or more NCDs) than men.¹⁸ Australian data also show that more women than men are currently living with multimorbidity.¹⁹

Although diverse conditions fall under the umbrella of NCDs, many of them share five major common preventable risk factors: tobacco use, physical inactivity, harmful use of alcohol, unhealthy diet and air pollution.⁵ While the burden attributable to some risk factors among women decreased between 2000 and 2021, there have been increases for many cardiometabolic risk factors, including high levels of systolic blood pressure (contributing to 11% of NCD deaths in women aged 15–49 years globally in 2021), elevated fasting plasma glucose (6%), elevated low-density lipoprotein cholesterol (7%), and other risk factors related to obesity and metabolic syndrome.^{7, 20} The burden from low physical activity and some dietary aspects (low intake of fruits, whole grains and vegetables; high intake of sodium) slightly increased. Ambient particulate matter pollution remained a leading contributor to DALYs.²⁰ Exposure to NCD risk factors is further increased by the effects of climate change,⁶ which have a disproportionate impact on women.²¹

Risk factors for NCDs accrue over a woman's life course, and prognosis worsens the longer NCDs are left untreated. NCDs during pregnancy affect maternal morbidity, mortality and long term health, child morbidity and mortality, and in some cases have intergenerational effects.²² The NCDs more commonly affecting pregnant women include hypertension, diabetes, asthma, epilepsy and mental health conditions.²² As 80–90% of women conceive in their lifetime,¹⁹ a life course approach to women's health (that views pregnancy within a continuum) rather than a focus on sexual or reproductive conditions increases opportunities for clinicians and policy makers to implement screening, prevention, education and treatment of NCDs.³

While it is crucial that health services also take steps to prevent NCDs in women earlier in the life course,²³ improving sexual, reproductive, maternal, newborn and child health (SRMNCH) services to address NCDs will improve outcomes for women not only during pregnancy, childbirth and the postnatal period but across the life course.²²

There are many challenges to addressing NCDs in the context of SRMNCH services. At the most fundamental level, these include a lack of reliable prevalence data and inconsistent definitions of NCDs, which limit the accurate data collection and monitoring needed to guide policy change.²⁴ Further challenges include inadequate high quality evidence (addressing all clinically important conditions, pregnancy stages and contexts) and comprehensive clinical practice guidelines, both of which inform optimal, evidence-based care.^{25, 26} There is also a lack of evidence for the safety of medications in pregnancy and for sex differences in the effectiveness and safety of different medications.²⁷

At the provider level, maternity care is often under-resourced. High quality care stretches beyond the antenatal and intrapartum periods, including preconception care and counselling, and long term chronic care. Although steps have been taken to integrate NCD and SRMNCH care in HICs, evidence of the effectiveness of such integration in LMICs is more limited.²⁸ An additional barrier is the lack of training and resources for health workers to competently detect and care for NCDs in pregnant women²² (Box 3).

Strategies to prevent hypertension and hyperglycaemia in young women before pregnancy could significantly benefit maternal health, but even approaches that are cost-effective and available are not universally implemented.²³

Gender inequality leads to worse health-related consequences for women, especially women from lower socio-economic groups.¹³ Although integrated NCD and SRMNCH care may improve access, social barriers to adequate ongoing care may remain. In some patriarchal settings, the health of women is a lower priority than that of other family members, and power imbalances and financial dependence restrict women's ability to access medical care.³ In addition, there are disparities in health equity research between high- and low-resource settings, with limited research available from LMICs on women's experience and health care disparities to drive policy change.²⁴

It is incumbent on policy makers, researchers and clinicians to take action to reduce preventable maternal deaths due to NCDs.

Significant reduction of premature deaths from NCDs in women and preventable maternal morbidity and mortality will only be achieved if NCDs and SRMNCH are addressed together. Pregnancy provides an ideal opportunity to improve NCD-related outcomes for women, enabling lifelong benefits. Progress can be made by agreeing on standard definitions of NCDs, improving primary prevention including climate mitigation measures that reduce risk factors, taking action to address health inequities, gender inequality, and structural disadvantage, integrating NCD and SRNMCH services and providing high quality evidence-based guidelines that address the most important clinical questions for women and clinicians.

Open access publishing facilitated by The University of Sydney, as part of the Wiley – The University of Sydney agreement via the Council of Australian University Librarians.

Doris Chou has worked with HRP, Helmsley Foundation and the United States Agency for International Development. She has received a grant from Global NCD Platform, travel reimbursements to attend the Society for Maternal-Fetal Medicine meeting. Jenny Ramson and Myfanwy Williams are contractors for the World Health Organization (WHO) and have received travel reimbursements from WHO. Bosede Afolabi received funding from the Tertiary Education Trust Fund, Nigeria for a clinical trial (the PIPSICKLE trial examining the effectiveness of low dose aspirin versus placebo in preventing intrauterine growth restriction in pregnant women with sickle cell disease). Bosede received honoraria from the American Society of Hematology for a presentation, and travel reimbursements from the American Society of Hematology and National Heart, Lung, and Blood Institute/National Institutes of Health (USA). Stephen Colagiuri is an honorary board member for the Juvenile Arthritis Foundation Australia Board and the Glycaemic Index Foundation Board. Kenneth Finlayson received consultancy fees from WHO as part of a program of work to support guideline development. Kartik Venkatesh received honoraria from the American Diabetes Association and grants from the US National Institutes of Health, Patient-Centered Outcomes Research Institute and Agency for Healthcare Research. He is on the Obstetrics and Gynecology (Green Journal) editorial board and is an associate editor of the Society of Maternal Fetal Medicine – American Journal of OG/GYN Special Edition.

Commissioned; externally peer reviewed.